Stephan Tarlach

Wölbern Private Equity GmbH (Wölbern-PE) is the private equity subsidiary of Germany-based Wölbern Group KG, controlled by Heinrich Schulte, MD, PhD. Established in 2006, the firm is headquartered in Hamburg and focuses primarily on private equity fund-of-fund management. Their clients are German private investors. The Wölbern group also manages direct private equity investments through Wölbern EquityPartner AG, the wholly-owned subsidiary of Bankhaus Wölbern Bankhaus Wölbern & Co. (AG & Co. KG).

Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany.